NCT01840735View on ClinicalTrials.gov

Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions

Cystic Fibrosis

Interventions

DRUG

GS-5737

DRUG

Placebo

Trial Locations (1)

32806

Compass Research Phase 1, LLC, Orlando

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT01840735 - Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF | Biotech Hunter | Biotech Hunter